<DOC>
	<DOCNO>NCT01060384</DOCNO>
	<brief_summary>The purpose trial investigate efficacy ( well drug work ) ofatumumab lenalidomide patient lymphoma investigate possible unwanted side effect may occur . The purpose Phase I portion trial determine maximum dose medication give minimal side effect .</brief_summary>
	<brief_title>Study Lenalidomide Ofatumumab Treatment Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis CD20+ nonHodgkin 's lymphoma recurrent refractory least one prior therapy potentially curative therapy available . Subject , age &gt; = 19 year Patients must relapse refractory disease least one prior systemic therapy , least 3 week interval completion recent chemotherapy radiotherapy regimen ( unless patient progressive disease prior 3 week ) . Patient resolve toxicity ≤ grade 1 , felt related prior therapy . Patients must ineligible relapsed autologous allogeneic stem cell transplant clinically appropriate . Adequate Laboratory Parameters : ANC ≥ 1500/μL Platelet count ≥75,000/μL Total bilirubin ≤ 1.5 time institutional Upper Limit Normal ( ULN ) unless due NHL Hepatic enzyme ( AST , ALT ) ≤ 2.5 time institutional ULN unless due NHL Serum Creatinine &lt; 3.0 time institutional ULN unless due NHL Creatinine clearance ≥60ml/min phase I ( See Appendix A ) Creatinine clearance ≥ 30ml/min phase II patient creatinine clearance ≥ 30ml/min &lt; 60ml/min start Lenalidomide reduce dose . See Section 5.3.1 Females childbearing potential ( FCBP ) must agree : Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prior prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . See Appendix B : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods . Note : A FCBP sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal ( i.e. , amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Male patient must : Agree use condom sexual contact FCBP , even vasectomy , throughout study drug therapy , dose interruption 28 day cessation study therapy . Agree donate semen study drug therapy period end study drug therapy ECOG Performance status 02 ( See Appendix C ) Signed write informed consent include HIPAA accord institutional guideline No malignancy [ one treat study ] require systemic treatment within past 3 year . Patients willing take DVT prophylaxis Pregnant lactating female Positive serology hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform positive subject exclude . Patients documented vaccination Hepatitis B consider positive . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Patients ≥ Grade 2 neuropathy Active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Known CNS involvement lymphoma Significant concurrent , uncontrolled medical condition , judgment investigator , may affect patient 's ability sign inform consent comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>